JP2023517729A5 - - Google Patents

Info

Publication number
JP2023517729A5
JP2023517729A5 JP2022555821A JP2022555821A JP2023517729A5 JP 2023517729 A5 JP2023517729 A5 JP 2023517729A5 JP 2022555821 A JP2022555821 A JP 2022555821A JP 2022555821 A JP2022555821 A JP 2022555821A JP 2023517729 A5 JP2023517729 A5 JP 2023517729A5
Authority
JP
Japan
Prior art keywords
process according
disorders
pharmaceutical composition
monohydrochloride salt
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/056749 external-priority patent/WO2021185878A1/en
Publication of JP2023517729A publication Critical patent/JP2023517729A/ja
Publication of JP2023517729A5 publication Critical patent/JP2023517729A5/ja
Priority to JP2025132332A priority Critical patent/JP2025166092A/ja
Pending legal-status Critical Current

Links

JP2022555821A 2020-03-19 2021-03-17 Taar1アゴニストの塩形態および結晶形態 Pending JP2023517729A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025132332A JP2025166092A (ja) 2020-03-19 2025-08-07 Taar1アゴニストの塩形態および結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
EP20164069.5 2020-03-19
PCT/EP2021/056749 WO2021185878A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025132332A Division JP2025166092A (ja) 2020-03-19 2025-08-07 Taar1アゴニストの塩形態および結晶形態

Publications (2)

Publication Number Publication Date
JP2023517729A JP2023517729A (ja) 2023-04-26
JP2023517729A5 true JP2023517729A5 (cg-RX-API-DMAC7.html) 2024-03-26

Family

ID=69846246

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022555821A Pending JP2023517729A (ja) 2020-03-19 2021-03-17 Taar1アゴニストの塩形態および結晶形態
JP2025132332A Pending JP2025166092A (ja) 2020-03-19 2025-08-07 Taar1アゴニストの塩形態および結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025132332A Pending JP2025166092A (ja) 2020-03-19 2025-08-07 Taar1アゴニストの塩形態および結晶形態

Country Status (13)

Country Link
US (1) US12692256B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121428B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023517729A (cg-RX-API-DMAC7.html)
KR (1) KR20220155575A (cg-RX-API-DMAC7.html)
CN (1) CN115279752A (cg-RX-API-DMAC7.html)
AU (1) AU2021238632A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016746A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166331A1 (cg-RX-API-DMAC7.html)
ES (1) ES3044409T3 (cg-RX-API-DMAC7.html)
IL (1) IL294301A (cg-RX-API-DMAC7.html)
MX (1) MX2022010794A (cg-RX-API-DMAC7.html)
TW (1) TWI874616B (cg-RX-API-DMAC7.html)
WO (1) WO2021185878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119654138A (zh) * 2022-08-12 2025-03-18 豪夫迈·罗氏有限公司 包含5-乙基-4-甲基-n-[4-[(2s)吗啉-2-基]苯基]-1h-吡唑-3-甲酰胺的药物组合物
TW202444712A (zh) * 2023-04-28 2024-11-16 大陸商江蘇豪森藥業集團有限公司 一種嗎啉雜環類化合物的鹽及其製備方法和應用
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
RS60825B1 (sr) * 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a

Similar Documents

Publication Publication Date Title
US20240317687A1 (en) Salt of omecamtiv mecarbil and process for preparing salt
TWI322805B (cg-RX-API-DMAC7.html)
CN1582278A (zh) 多晶型rimonabant,其制备方法及含有它的药物组合物
CN1612863A (zh) 氘代的取代的吡唑基-苯磺酰胺以及包含该化合物的药物组合物
TW201033181A (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
JP2011529480A (ja) ラサジリンメシレートの多型
WO2016107289A1 (zh) 制备索非布韦晶型6的方法
CN1602304A (zh) 氘代的取代的二氢呋喃酮以及包含该化合物的药物组合物
CN1805953A (zh) 用作血清素再摄取抑制剂的吲哚衍生物
CN1443178A (zh) (r)-n-[5-甲基-8-(4-甲基哌嗪-1-基)-1,2,3,4-四氢-2-萘基]-4-吗啉代苯甲酰胺的新形态
US20100035994A1 (en) Novel hydrate form of o-desmethyl venlafaxine succinate
KR101557832B1 (ko) (r)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
CN1452614A (zh) 芳基哌嗪衍生物及其作为精神药物的用途
FR2643634A1 (fr) Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
TW200817322A (en) Compounds having activity at the GlyT1 transporter
JP2008530040A (ja) トランス−1−((1r,3s)−6−クロロ−3−フェニルインダン−1−イル)−3,3−ジメチルピペラジンの結晶質塩基
CN1880294B (zh) 右酮洛芬氨丁三醇的多晶型、其制备方法和包含它的组合物
JP2004526692A (ja) 純粋な塩酸オンダンセトロン二水和物を製造するための改良された方法
JPS584765A (ja) 新規インド−ル誘導体、その製法及び該化合物を含有するβ−受容体刺激性、抗アレルギ−性、消炎性及び鎮痛性医薬調剤
CN119039301B (zh) 一种含氮杂环的多环化合物晶型ⅰ的制备方法
TWI787008B (zh) 右美托咪定鹽酸鹽之製造方法
TWI886914B (zh) -3-酮衍生物枸櫞酸鹽的晶型、製備方法及其用途
CN1029737C (zh) 新氨烷基酮衍生物的制备方法
WO2009110519A1 (ja) 新規1-アミノカルボニルピペリジン誘導体
JP6595990B2 (ja) アゴメラチンとスルホン酸との新規な複合体、これらの製造方法及びこれらを含有する医薬組成物